Celgene and Forma Therapeutics are expanding their already extensive relationship. The Summit, NJ-based drugmaker has exercised a $195 million option to widen the breadth of the 2014 deal it signed with Forma to co-develop drugs for cancer and other therapeutic areas—an agreement that gave Celgene (NASDAQ: CELG) the option to buy Forma down the road. […]
NYS Entity Status
NYS Filing Date
MARCH 18, 2014
NYS DOS ID#
RACHEL A HOROWITZ
13 E 124TH ST., 3B
NEW YORK, NEW YORK, 10035
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - FORMA DE SER LLC
Around the Web
- Celgene Broadens Forma Deal, Adding $195M More for Drug R&D
By Frank Vinluan - Tuesday Aug 29, 2017
- In the Studio: Oscar de la Renta’s New Designers Have a Hillary Clinton Story to Share
By VANESSA FRIEDMAN - Sunday Sep 10, 2017
And other secrets contained in their office walls.
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- The Mayor and the Restaurateur: How de Blasio Sought Help for an Early Donor
By WILLIAM NEUMAN and WILLIAM K. RASHBAUM - Monday Jul 24, 2017
Federal investigators, while declining to prosecute, still questioned City Hall’s conduct. Was the administration doing favors for contributors?